Posted by Michael Wonder on 31 May 2017
European Commission approves Pfizer's Trumenba to help prevent meningococcal Group B disease in adolescents and adults
30 May 2017 - Trumenba approved in Europe with option for a two or three dose schedule.
Pfizer announced today that the European Commission has approved Trumenba (Meningococcal Group B Vaccine) for the prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroup B (MenB) in individuals 10 years of age and older.
Adolescents and young adults are a critical demographic for vaccination against MenB due to inherent environmental and social risk factors such as close-quartered living and sharing behaviours.
